氨溴索联合噻托溴铵对COPD合并肺结核患者免疫功能及预后的影响
|
摘要
目的分析氨溴索联合噻托溴铵对COPD合并肺结核患者的疗效,为临床治疗提供参考。方法选取2017年1月至2018年12月医院收治的162例COPD合并肺结核患者,随机分为对照组、研究组。对照组给予常规治疗,研究组在常规治疗基础上予以氨溴索联合噻托溴铵治疗,两组持续治疗10周后比较其各项预后指标和免疫功能指标。结果研究组有效率高于对照组,病灶吸收情况优于对照组,CD_3~+、CD_4~+细胞水平高于对照组,CD_8~+细胞水平及CD_(64)指数低于对照组,上述差异均具有统计学意义(P<0.05)。结论氨溴索联合噻托溴铵能提高COPD合并肺结核患者的预后效果,提高患者的免疫力,值得在临床中做进一步推广。
Objective To analyze the efficacy of ambroxol combined with tiotropium bromide in patients with COPD and pulmonary tuberculosis, and provide reference for clinical treatment.Methods A total of 162 patients with COPD and pulmonary tuberculosis admitted to the hospital from January 2016 to December 2017 were randomly divided into the control group and the study group. The control group received routine treatment. The study group received ambroxol combined with tiotropium bromide on the basis of conventional treatment. The prognostic indicators and immune function indexes were compared after 10 weeks of continuous treatment.Results The effective rate of the study group was higher than that of the control group. The lesion absorption was better than that of the control group. The CD3+, CD4+, NK cells were higher than the control group, the CD8+ cell level and the CD64 index were lower than the control group. The above differences were statistically significant(P<0.05). Conclusion Ambroxol combined with tiotropium can improve the prognosis of patients with COPD and pulmonary tuberculosis and improve their immunity. It is worth further promotion in the clinic.
Objective To analyze the efficacy of ambroxol combined with tiotropium bromide in patients with COPD and pulmonary tuberculosis, and provide reference for clinical treatment.Methods A total of 162 patients with COPD and pulmonary tuberculosis admitted to the hospital from January 2016 to December 2017 were randomly divided into the control group and the study group. The control group received routine treatment. The study group received ambroxol combined with tiotropium bromide on the basis of conventional treatment. The prognostic indicators and immune function indexes were compared after 10 weeks of continuous treatment.Results The effective rate of the study group was higher than that of the control group. The lesion absorption was better than that of the control group. The CD3+, CD4+, NK cells were higher than the control group, the CD8+ cell level and the CD64 index were lower than the control group. The above differences were statistically significant(P<0.05). Conclusion Ambroxol combined with tiotropium can improve the prognosis of patients with COPD and pulmonary tuberculosis and improve their immunity. It is worth further promotion in the clinic.
引文
[1] 蔡柏蔷.慢性阻塞性肺疾病诊断、处理和预防全球策略(2017 GOLD报告)解读[J].国际呼吸杂志,2017,37(1):6-17.
[2] 张悦,于晓江.舒适护理改善ICU慢性阻塞性肺疾病并肺心病患者肺部感染作用的分析[J].实用临床医药杂志,2017,21(8):30-33.
[3] 王蕾,杨汀,王辰.2017年版慢性阻塞性肺疾病诊断、处理和预防全球策略解读[J].中国临床医生杂志,2017,45(1):104-108.
[4] 龚峰,张晓调,陈显静,等.慢性阻塞性肺疾病急性加重患者相关病毒感染的危险因素分析[J].中华医院感染学杂志,2017,27(4):800-803.
[5] 姚文飞,屠春林,赵开顺,等.慢性阻塞性肺疾病的肺康复研究进展[J].临床肺科杂志,2017,22(02):163-166.
[6] 陈荣昌,赵东兴.应重视中国慢性阻塞性肺疾病的疾病负担和患者特点[J].中华医学杂志,2017,97(40):3121.
[7] 殷晓娜,宋卫东.慢性阻塞性肺疾病评估测试方法的比较研究[J].临床肺科杂志,2017,22(4):645-649.
[8] Hobbs B D,Jong K D,Lamontagne M,et al.Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis[J].Nature Genetics,2017,49(3):426-432.
[9] Singh S,Verma S K,Kumar S,et al.Evaluation of Oxidative Stress and Antioxidant Status in Chronic Obstructive Pulmonary Disease[J].Scandinavian Journal of Immunology,2017,85(2):130-137.
[10] 李雪英,胡苏萍,陈国忠,等.炎症反应与慢性阻塞性肺疾病相关肺动脉高压及其血液高凝状态的关系[J].山东医药,2017,57(01):77-79.
[11] 丁守华,万青灵,邵文荣,等.江苏淮安市2011—2015年肺结核流行病学分析[J].中国热带医学,2017,17(8):791-794.
[12] 周新华.重视肺结核及其并发病变的影像学分析与诊断[J].中国防痨杂志,2017,39(6):552-554.
[13] Van d P J,Klein J J,Kerkhoff A H,et al.Evaluation of the effectiveness of four different inhalers in patients with chronic obstructive pulmonary disease.[J].Thorax,2017,50(11):1183-7.
[14] 曹仕鹏,李春香,邱淑梗,等.老年慢性阻塞性肺疾病合并肺结核的临床特点及诊治体会[J].广西医学,2017,39(5):585-589.
[15] 宋宏颖.慢性阻塞性肺疾病合并肺结核患者免疫功能及其细胞因子水平变化[J].山东医药,2017,57(25):85-87.
[2] 张悦,于晓江.舒适护理改善ICU慢性阻塞性肺疾病并肺心病患者肺部感染作用的分析[J].实用临床医药杂志,2017,21(8):30-33.
[3] 王蕾,杨汀,王辰.2017年版慢性阻塞性肺疾病诊断、处理和预防全球策略解读[J].中国临床医生杂志,2017,45(1):104-108.
[4] 龚峰,张晓调,陈显静,等.慢性阻塞性肺疾病急性加重患者相关病毒感染的危险因素分析[J].中华医院感染学杂志,2017,27(4):800-803.
[5] 姚文飞,屠春林,赵开顺,等.慢性阻塞性肺疾病的肺康复研究进展[J].临床肺科杂志,2017,22(02):163-166.
[6] 陈荣昌,赵东兴.应重视中国慢性阻塞性肺疾病的疾病负担和患者特点[J].中华医学杂志,2017,97(40):3121.
[7] 殷晓娜,宋卫东.慢性阻塞性肺疾病评估测试方法的比较研究[J].临床肺科杂志,2017,22(4):645-649.
[8] Hobbs B D,Jong K D,Lamontagne M,et al.Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis[J].Nature Genetics,2017,49(3):426-432.
[9] Singh S,Verma S K,Kumar S,et al.Evaluation of Oxidative Stress and Antioxidant Status in Chronic Obstructive Pulmonary Disease[J].Scandinavian Journal of Immunology,2017,85(2):130-137.
[10] 李雪英,胡苏萍,陈国忠,等.炎症反应与慢性阻塞性肺疾病相关肺动脉高压及其血液高凝状态的关系[J].山东医药,2017,57(01):77-79.
[11] 丁守华,万青灵,邵文荣,等.江苏淮安市2011—2015年肺结核流行病学分析[J].中国热带医学,2017,17(8):791-794.
[12] 周新华.重视肺结核及其并发病变的影像学分析与诊断[J].中国防痨杂志,2017,39(6):552-554.
[13] Van d P J,Klein J J,Kerkhoff A H,et al.Evaluation of the effectiveness of four different inhalers in patients with chronic obstructive pulmonary disease.[J].Thorax,2017,50(11):1183-7.
[14] 曹仕鹏,李春香,邱淑梗,等.老年慢性阻塞性肺疾病合并肺结核的临床特点及诊治体会[J].广西医学,2017,39(5):585-589.
[15] 宋宏颖.慢性阻塞性肺疾病合并肺结核患者免疫功能及其细胞因子水平变化[J].山东医药,2017,57(25):85-87.